EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Fotagliptin add‐on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double‐blind, placebo‐controlled, phase 3 trial

Nan Yu iD, Wenjie Xu, Xiaohui Guo, Mingtong Xu, Wei Zhang, Chaoli Yan, Shuguang Pang, Xiuhai Shu, Wei Zhang, Weixia Peng, Yawei Zhang, Gaixian Li und 2 weitere

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16427 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Nan Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin, Hypoglycemic Agents, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shenzhen Salubris Pharmaceuticals Co.,Ltd, Shenzhen Science and Technology Program for Undertake the National Science and Technology Major Project, Shenzhen Salubris Pharmaceuticals Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Fotagliptin is a novel dipeptidyl peptidase‐4 inhibitor for glycaemic control in patients with type 2 diabetes (T2D). This trial aimed to assess the efficacy and safety of fotagliptin add‐on to metformin in patients with T2D. Materials and Methods In this phase 3 randomised, double‐blind, placebo‐controlled study, patients with T2D who had inadequate glycaemic control using metformin alone were randomly allocated to fotagliptin or placebo at a 2:1 ratio for 24‐week double‐blind treatment period, followed by an open‐label treatment with fotagliptin for all patients, making up a total of 52 weeks. All eligible patients were treated with a stable dose of metformin (≥1500 mg per day). The primary endpoint was the change in HbA1c level from baseline to week 24. Safety was assessed in all patients who received at least one dose of the study drug.

Results

After 24 weeks, LS mean change of HbA1c from baseline was −0.81% with fotagliptin versus −0.28% with placebo. Estimated treatment difference for fotagliptin versus placebo of HbA1c was −0.53% (95% confidence interval [CI] −0.68% to −0.39%; p < 0.001). Significantly more patients on fotagliptin than on placebo achieved HbA1c < 7.0% after 24 weeks (38.7% vs. 16.9%; p < 0.001). The incidence of adverse events was similar between the two groups. No severe hypoglycaemia events were reported in patients treated with fotagliptin and metformin combined therapy.

Conclusions

In patients with T2D who experienced inadequate glycaemic control with metformin, fotagliptin achieved a superior and clinically meaningful improvement in glycaemic control compared with placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2MetforminHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsHumansDouble-Blind MethodMaleFemaleMiddle AgedDrug Therapy, CombinationAgedGlycated HemoglobinBlood GlucoseTreatment OutcomeAdultHypoglycemia

Stichwörter der Autor:innen

HbA1cdipeptidyl peptidase‐4 inhibitorsfotagliptinmetformintype 2 diabetes

Substanzen

MetforminHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsGlycated HemoglobinBlood Glucosehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Peking University First Hospital, Beijing, China.
  • Shenzhen Salubris Pharmaceuticals Co., Ltd, Shenzhen, China.
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • The First Hospital of Qiqihar, Qiqihar, China.
  • The Affiliated Hospital of Inner Mongolia Medical University, Huhehaote, China.
  • Certer Hospital Affiliated to Shandong First Medical University, Jinan, China.

ORCID-Profile: Nan Yu

Förderung

  • Shenzhen Salubris Pharmaceuticals Co.,Ltd
  • Shenzhen Science and Technology Program for Undertake the National Science and Technology Major Project
  • Shenzhen Salubris Pharmaceuticals Co., Ltd

Zitieren

APA

Yu, N., Xu, W., Guo, X., Xu, M., Zhang, W., Yan, C., Pang, S., Shu, X., Zhang, W., Peng, W., Zhang, Y., Li, G., Zhang, X., & Zhou, D. (2025). Fotagliptin add‐on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double‐blind, placebo‐controlled, phase 3 trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16427

Vancouver

Yu N, Xu W, Guo X, Xu M, Zhang W, Yan C, et al. Fotagliptin add‐on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double‐blind, placebo‐controlled, phase 3 trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16427

BibTeX
@article{Yu2025,
  author = {Yu, Nan and Xu, Wenjie and Guo, Xiaohui and Xu, Mingtong and Zhang, Wei and Yan, Chaoli and Pang, Shuguang and Shu, Xiuhai and Zhang, Wei and Peng, Weixia and Zhang, Yawei and Li, Gaixian and Zhang, Xin and Zhou, Dongmei},
  title = {Fotagliptin add‐on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double‐blind, placebo‐controlled, phase 3 trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16427}
}
Kostenlos starten →